Shots:

• Secarna to receive an upfront along with an option exercise fees & is also eligible to receive development & commercial milestone along with royalties on net sales of personalized T cell therapies which are developed & commercialized from the collaboration
• The collaboration will combine Secarna’s industry-leading ASO platform, LNAplus with Achilles’ expertise to develop optimized T cell therapies for cancer patients
• Secarna’s LNAplus has proved to be a fast, reliable, scalable & efficient drug discovery platform that contains all aspects of discovery & pre-clinical development & allows the discovery of novel antisense-based therapies against undruggable targets in immune-oncology

  Ref: Secarna Pharmaceuticals | Image: Secarna Pharmaceuticals